ULBP1 and glioblastoma: The expression levels of NK ligands (CD155, CD112, MICA/B, ULBP1, and PDL1) on GBM cells (U87, U118, and U343) and primary GBM cells (pGBM) before and after the treatments with Bev (0.5 mg/mL) and Iri (0.15 mg/mL) at 24 h were elucidated via flow cytometry (Figures 1J–M; S1).